Sort by

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 84


Unlocking ATP13A2/PARK9 activity.

Martin S, Holemans T, Vangheluwe P.

Cell Cycle. 2015;14(21):3341-2. doi: 10.1080/15384101.2015.1093420. No abstract available.


A lipid switch unlocks Parkinson's disease-associated ATP13A2.

Holemans T, Sørensen DM, van Veen S, Martin S, Hermans D, Kemmer GC, Van den Haute C, Baekelandt V, Günther Pomorski T, Agostinis P, Wuytack F, Palmgren M, Eggermont J, Vangheluwe P.

Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):9040-5. doi: 10.1073/pnas.1508220112.


The Parkinson-associated human P5B-ATPase ATP13A2 protects against the iron-induced cytotoxicity.

Rinaldi DE, Corradi GR, Cuesta LM, Adamo HP, de Tezanos Pinto F.

Biochim Biophys Acta. 2015 Aug;1848(8):1646-55. doi: 10.1016/j.bbamem.2015.04.008.


Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review.

Yang X, Xu Y.

Biomed Res Int. 2014;2014:371256. doi: 10.1155/2014/371256. Review.


Identification of p.Gln858* in ATP13A2 in two EOPD patients and presentation of their clinical features.

Malakouti-Nejad M, Shahidi GA, Rohani M, Shojaee SM, Hashemi M, Klotzle B, Fan JB, Elahi E.

Neurosci Lett. 2014 Aug 8;577:106-11. doi: 10.1016/j.neulet.2014.06.023.


Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction.

Park JS, Koentjoro B, Veivers D, Mackay-Sim A, Sue CM.

Hum Mol Genet. 2014 Jun 1;23(11):2802-15. doi: 10.1093/hmg/ddt623.


ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies.

Murphy KE, Cottle L, Gysbers AM, Cooper AA, Halliday GM.

Acta Neuropathol Commun. 2013 May 9;1:11. doi: 10.1186/2051-5960-1-11.


The role of the Ala746Thr variant in the ATP13A2 gene among Chinese patients with Parkinson's disease.

Chan AY, Baum L, Tang NL, Lau CY, Ng PW, Hui KF, Mizuno Y, Kwan JY, Mok VC, Kuo SH.

J Clin Neurosci. 2013 May;20(5):761-2. doi: 10.1016/j.jocn.2012.05.052.


Parkinson's disease-associated human P5B-ATPase ATP13A2 increases spermidine uptake.

De La Hera DP, Corradi GR, Adamo HP, De Tezanos Pinto F.

Biochem J. 2013 Feb 15;450(1):47-53. doi: 10.1042/BJ20120739.


Interaction of divalent cations with peptide fragments from Parkinson's disease genes.

Remelli M, Peana M, Medici S, Delogu LG, Zoroddu MA.

Dalton Trans. 2013 May 7;42(17):5964-74. doi: 10.1039/c2dt32222f.


ATP13A2 knockout does not affect the infarct size in mice with acute ischemic stroke.

Yu JG, Cui MJ, Wang W, Hu KB, Cai GJ.

CNS Neurosci Ther. 2012 Dec;18(12):1027-9. doi: 10.1111/cns.12023. No abstract available.


Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove.

Dehay B, Martinez-Vicente M, Ramirez A, Perier C, Klein C, Vila M, Bezard E.

Autophagy. 2012 Sep;8(9):1389-91. doi: 10.4161/auto.21011.


Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants.

Covy JP, Waxman EA, Giasson BI.

J Neurosci Res. 2012 Dec;90(12):2306-16. doi: 10.1002/jnr.23112.


Analysis of ATP13A2 in large neurodegeneration with brain iron accumulation (NBIA) and dystonia-parkinsonism cohorts.

Kruer MC, Paudel R, Wagoner W, Sanford L, Kara E, Gregory A, Foltynie T, Lees A, Bhatia K, Hardy J, Hayflick SJ, Houlden H.

Neurosci Lett. 2012 Aug 8;523(1):35-8. doi: 10.1016/j.neulet.2012.06.036.


Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration.

Dehay B, Ramirez A, Martinez-Vicente M, Perier C, Canron MH, Doudnikoff E, Vital A, Vila M, Klein C, Bezard E.

Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9611-6. doi: 10.1073/pnas.1112368109.


Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis.

Bras J, Verloes A, Schneider SA, Mole SE, Guerreiro RJ.

Hum Mol Genet. 2012 Jun 15;21(12):2646-50. doi: 10.1093/hmg/dds089.


Mn(II) and Zn(II) interactions with peptide fragments from Parkinson's disease genes.

Medici S, Peana M, Delogu LG, Zoroddu MA.

Dalton Trans. 2012 Apr 21;41(15):4378-88. doi: 10.1039/c2dt12168a.


ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome.

Grünewald A, Arns B, Seibler P, Rakovic A, Münchau A, Ramirez A, Sue CM, Klein C.

Neurobiol Aging. 2012 Aug;33(8):1843.e1-7. doi: 10.1016/j.neurobiolaging.2011.12.035.


Hypoxia regulation of ATP13A2 (PARK9) gene transcription.

Xu Q, Guo H, Zhang X, Tang B, Cai F, Zhou W, Song W.

J Neurochem. 2012 Jul;122(2):251-9. doi: 10.1111/j.1471-4159.2012.07676.x.

Items per page

Supplemental Content

Support Center